Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

20
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
20
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

26
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
26
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

18
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
18
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

13
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
13
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

21
Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
21
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

14
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
14

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Contemporary medical management of left ventricular assist device patients: integrating sex-specific perspectives.

Current opinion in cardiology·2026
Same author

Cardiovascular Health Profiles in Pregnant, Postpartum, and Nonpregnant Reproductive-Aged Women Using Life's Essential 8 Scores.

JACC. Advances·2026
Same author

The novelty of anticoagulation in LVAD Therapy: Current Practice, the Role of Direct Oral Anticoagulants, and Future Directions.

Journal of cardiovascular pharmacology·2026
Same author

Does Pacemaker Mode Affect Outcomes in Patients With HeartMate 3 LVAD?

ASAIO journal (American Society for Artificial Internal Organs : 1992)·2026
Same author

The Association Between Social Determinants of Health, Race, and Sex on Risk for Readmission After Heart Transplantation.

Journal of cardiac failure·2026
Same author

Preservation Strategy and Sex-Specific Risk of Severe Primary Graft Dysfunction After Heart Transplantation: A GUARDIAN-Heart Analysis.

ASAIO journal (American Society for Artificial Internal Organs : 1992)·2026

Related Experiment Video

Updated: Aug 4, 2025

Real-Time Electrocardiogram Monitoring During Treadmill Training in Mice
04:45

Real-Time Electrocardiogram Monitoring During Treadmill Training in Mice

Published on: May 5, 2022

2.5K

Considerations for specific cardiomyopathies during pregnancy.

Madeline Abrams1, Ella Magun, Ersilia M DeFilippis

  • 1Center for Advanced Cardiac Care, Division of Cardiology, Columbia University Irving Medical Center, New York, New York, USA.

Current Opinion in Cardiology
|April 5, 2023
PubMed
Summary

Maternal cardiovascular disease, including cardiomyopathy, is a leading cause of pregnancy mortality. This review covers various cardiomyopathies during pregnancy, focusing on risk, management, and outcomes beyond peripartum cardiomyopathy.

More Related Videos

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

3.2K
Isolation and Physiological Analysis of Mouse Cardiomyocytes
11:02

Isolation and Physiological Analysis of Mouse Cardiomyocytes

Published on: September 7, 2014

23.2K

Related Experiment Videos

Last Updated: Aug 4, 2025

Real-Time Electrocardiogram Monitoring During Treadmill Training in Mice
04:45

Real-Time Electrocardiogram Monitoring During Treadmill Training in Mice

Published on: May 5, 2022

2.5K
Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

3.2K
Isolation and Physiological Analysis of Mouse Cardiomyocytes
11:02

Isolation and Physiological Analysis of Mouse Cardiomyocytes

Published on: September 7, 2014

23.2K

Area of Science:

  • Cardiology
  • Maternal-Fetal Medicine
  • Cardiovascular Disease in Pregnancy

Background:

  • Maternal mortality in the US is rising, with cardiovascular disease as a primary driver.
  • Cardiomyopathy and heart failure are significant contributors to pregnancy-related deaths.
  • Peripartum cardiomyopathy is common, but other cardiomyopathies also pose risks during pregnancy.

Approach:

  • This review synthesizes current knowledge on various cardiomyopathies during pregnancy.
  • It examines recent studies on preconception risk, counseling, and pharmacologic management.
  • Focus is placed on maternal outcomes in dilated, hypertrophic, arrhythmogenic right ventricular, noncompaction, and chemotherapy-induced cardiomyopathies.

Key Points:

  • Cardiomyopathy in pregnancy increases the risk of adverse cardiovascular events, morbidity, and mortality.
  • Preconception counseling and risk stratification are crucial for optimizing maternal outcomes.
  • Management strategies and outcomes vary across different types of cardiomyopathies during pregnancy.

Conclusions:

  • Recognizing and managing diverse cardiomyopathies in pregnancy is essential for improving maternal health.
  • Further research is needed for less common cardiomyopathies to establish standardized recommendations.
  • Optimizing antepartum management requires a comprehensive understanding of these conditions.